|
Thomas Pharmaceuticals Ltd. shares were distributed on November 21, 2007.
Thomas Pharmaceutical develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid+All ™, is a calcium-enriched, sugar free, anti-gas antacid tablet targeted to travelers, executives and baby boomers requiring antacid relief. The product is fully developed, and sample quantities have been submitted by an FDA approved contract manufacturer who can deliver production quantities within 60 days of receipt of a purchase order.
Thomas Pharmaceuticals is giving the over-the-counter antacid category a makeover when its stylish and soothing Acid+All™ hits the drug store scene this March. With the introduction of this sleekly packaged, high-end antacid, Thomas Pharmaceuticals adds a hip retro twist to the otherwise frumpy over-the-counter antacid category. Acid+All™ soothes heartburn with flair; its unique blue and white chicly designed tin harkens back to the days when apothecary products were packaged with panache -- a quality that today's upscale consumers are sure to covet.
“We’re looking for that consumer who wants substance with style,” said Tom Thomas, president and founder of Thomas Pharmaceuticals. “Acid+All™ relieves the increasingly common modern-day problem of heartburn while evoking another era – one of independent pharmacies and specialized products. This is an antacid that you’ll want to display; it's the ultimate premium accessory.”
The debut of Acid+All™ will be supported with advertising, sampling, sponsorships, public relations and special events. The advertising campaign, which broke on January 16th on the cover of Drug Store News, features Acid+All™ packages appearing as trendy accessories – such as a belt buckle on a well-dressed man and the handle on a designer purse. (Images available upon request.)
Acid+All™ will appear at the National Basketball Association’s New York Knicks and the National Hockey League’s New York Rangers games at Madison Square Garden in the form of radio spots and floor signage. Acid+All™ will also partner with the uber-luxury hotel chain, The Peninsula, for extensive sampling at its New York and Chicago locations. Additional partnerships will include The Brooklyn Academy of Music, Aspen Food + Wine Festival, Share Our Strength’s Taste of the Nation and other luxury partners.
Available in March 2006, the 32-count calcium enriched, spearmint-flavored and sugar free tablets will retail for approximately $2.99. Acid+All™ will be sold through independent pharmacies and drug stores. Thomas Pharmaceutical plans to introduce Acid+All™ line extensions later this year along with other new OTC products.
Trey Resources Spin-off
In February 2004, iVoice shareholders received one share of Trey Resources for every 1,793 shares held in iVoice. The successful Trey Resources spin-off demonstrated the feasibility of the mechanism and established further opportunities for both entities. Trey Resources closed on its first acquisition in June 2004 by acquiring an operating company with sales of over $2 million. Since that time, Trey has acquired two companies, hired the management of a third company, and grown from no sales to revenues at a current operating rate of nearly $4 million per annum.
iVoice Technology, Inc.
On Sept. 7, 2004, iVoice announced the anticipated distribution to the Company’s shareholders all common stock of a newly formed subsidiary, iVoice Technology, Inc. This move was designed to unlock the value in iVoice’s interactive voice recognition (IVR) software technology by transferring this technology to an independent public company, iVoice Technology, and thereafter distributing the common stock of this subsidiary to the Company’s shareholders. iVoice Technology will initially focus on building a business around the IVR technology. iVoice completed the spin-off of iVoice Technology and the distribution of iVoice Technology common stock to iVoice shareholders in the form of a special dividend in August 2005.
Deep Field Technologies, Inc.
On Sept. 13, 2004 iVoice announced that it intends to distribute to the company’s shareholders all common stock of a newly formed subsidiary, Deep Field Technologies, Inc., as a way to unlock the value in its Unified Messaging software technology. Unified Messaging links telephone systems to computer networks and allows users wherever they may be to access voice mail and retrieve e-mail in a single operation through existing local area networks. iVoice completed the spin-off of Deep Field Technologies and the distribution of Deep Field Technologies common stock to iVoice shareholders in the form of a special dividend in August 2005.
SpeechSwitch, Inc.
On November 5, 2004, announced that it intends to distribute to the Company’s shareholders all common stock shares of its newly formed subsidiary SpeechSwitch, Inc. The iVoice board of directors authorized management to pursue a strategy designed to unlock the value in the Company’s speech recognition software by spinning it off into a new independent public company, SpeechSwitch, Inc. iVoice completed the spin-off of SpeechSwitch and the distribution of SpeechSwitch common stock to iVoice shareholders in the form of a special dividend in August 2005. SpeechSwitch’s assets include the Speech SDK, Speech Enabled Auto Attendant, Name Dialer, plus two issued patents and two patents pending.
|
